Jeffrey Wolf, MD, on Next-Generation CAR T Cell Therapy and the Future of Multiple Myeloma Treatments

Video

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.

Jeffrey Wolf, MD, of the University of California San Francisco, discussed the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma in an interview with CancerNetwork.

Transcription:

This year, I’m seeing the results with T-cell engagers (TCE) and believing that, although we’re probably not curing anyone, we’re getting at least as good results as we are with CAR Ts, so maybe we’ve leapfrogged with TCEs beyond CAR Ts. But I’m looking forward, in the next few years, to next-generation CAR Ts, maybe dual CARs that will attack more than 1 target. And that will probably leapfrog the TCEs. So, I think ultimately, we’re going to be looking at either drugs or cells that are going to give us 3-4 years of control or cure. And I really think that we’re probably 5 years away from truly curing some of our patients.

Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.